ERBB2 and amenorrhea: Some women with HER2+ disease may receive a taxane and a platinum, such as carboplatin, and this regimen is thought to have less ovarian toxicity than ACT, though the rates of treatment-related amenorrhea are poorly characterized [17, 18].